Empirical Asset Management LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 929 shares of the medical research company’s stock, valued at approximately $466,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Wealth Managment LLC ID increased its stake in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the last quarter. Allied Private Wealth LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth $26,000. High Note Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $28,000. Finally, JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $28,000. Institutional investors own 89.23% of the company’s stock.
Insider Buying and Selling
In other news, VP Lisa P. Britt sold 5,850 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at $8,574,720. This trade represents a 28.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 52,053 shares of company stock valued at $30,643,589. Corporate insiders own 0.33% of the company’s stock.
Thermo Fisher Scientific Stock Up 4.3%
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Barclays raised their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.
View Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
